{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:26:25Z","timestamp":1792553185470,"version":"4.5.0"},"reference-count":48,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,7,9]],"date-time":"2023-07-09T00:00:00Z","timestamp":1688860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"University of Cyprus","award":["IAT 128\/2020"],"award-info":[{"award-number":["IAT 128\/2020"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>There are significant considerations about the prevention of cardiotoxicity caused by trastuzumab therapy in patients with breast cancer, leading to discontinuation. Recently, randomized controlled trials (RCTs) have evaluated the effects of early commitment of beta-blockers (BBs), angiotensin receptor blockers (ARBs) and angiotensin converting enzyme inhibitors (ACEIs) during trastuzumab chemotherapy in order to prevent the related cardiotoxicity. The present systematic review and meta-analysis of six RCTs included patients who have predominantly non-metastatic, HER2-positive, breast cancer and received trastuzumab as primary or adjuvant therapy. Those patients did not have any obvious cardiac dysfunction or any previous therapy with cardioprotective agent. We evaluated the efficacy of the aforementioned medications for primary prevention of cardiotoxicity, using random effects models. Any preventive treatment did not reduce cardiotoxicity occurrence compared to controls (Odds ratios (OR) = 0.92, 95% CI 0.54\u20131.56, p = 0.75). Results were similar for ACEIs\/ARBs and beta-blockers. Treatment with ACEIs\/ARBs led to a slight, but significant, increase in LVEF in patients compared to the placebo group. Only two studies reported less likelihood of discontinuation of trastuzumab treatment. More adequately powered RCTs are needed to determine the efficacy of routine prophylactic therapy.<\/jats:p>","DOI":"10.3390\/ph16070983","type":"journal-article","created":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T01:02:50Z","timestamp":1688950970000},"page":"983","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cardioprotective Agents for the Primary Prevention of Trastuzumab-Associated Cardiotoxicity: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"16","author":[{"given":"Kyriakos","family":"Goulas","sequence":"first","affiliation":[{"name":"Medical School, University of Cyprus, Nicosia 2029, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Farmakis","sequence":"additional","affiliation":[{"name":"Medical School, University of Cyprus, Nicosia 2029, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5316-7574","authenticated-orcid":false,"given":"Anastasia","family":"Constantinidou","sequence":"additional","affiliation":[{"name":"Medical School, University of Cyprus, Nicosia 2029, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7830-3488","authenticated-orcid":false,"given":"Nikolaos P. E.","family":"Kadoglou","sequence":"additional","affiliation":[{"name":"Medical School, University of Cyprus, Nicosia 2029, Cyprus"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,9]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3322\/caac.21754","article-title":"Breast Cancer Statistics, 2022","volume":"72","author":"Giaquinto","year":"2022","journal-title":"CA A Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"20211033","DOI":"10.1259\/bjr.20211033","article-title":"Understanding Breast Cancer as a Global Health Concern","volume":"95","author":"Wilkinson","year":"2022","journal-title":"Br. J. Radiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.3389\/fcvm.2021.821663","article-title":"The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment","volume":"8","author":"Lin","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/annonc\/mdv013","article-title":"Risk of Subsequentin Situ and Invasive Breast Cancer in Human Epidermal Growth Factor Receptor 2-Positive Ductal Carcinomain Situ","volume":"26","author":"Curigliano","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"5700","DOI":"10.1200\/JCO.2009.23.2025","article-title":"High Risk of Recurrence for Patients with Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2\u2013Positive, Node-Negative Tumors 1 Cm or Smaller","volume":"27","author":"Litton","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1200\/JCO.1992.10.4.599","article-title":"HER-2\/Neu in Node-Negative Breast Cancer: Prognostic Significance of Overexpression Influenced by the Presence of in Situ Carcinoma","volume":"10","author":"Allred","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"ref_7","first-page":"4960","article-title":"Her-2\/Neu Expression in Node-Negative Breast Cancer: Direct Tissue Quantitation by Computerized Image Analysis and Association of Overexpression with Increased Risk of Recurrent Disease","volume":"53","author":"Press","year":"1993","journal-title":"Cancer Res."},{"key":"ref_8","unstructured":"(2023, April 28). Trastuzumab: A Medicine to Treat Some Types of Cancer. nhs.uk. Available online: https:\/\/www.nhs.uk\/medicines\/trastuzumab-herceptin."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s40259-016-0162-9","article-title":"Trastuzumab in the Treatment of Breast Cancer","volume":"30","author":"Maximiano","year":"2016","journal-title":"BioDrugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant Trastuzumab in HER2-Positive Breast Cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"New Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1159\/000488202","article-title":"Overall Survival Benefit from Trastuzumab-Based Treatment in HER2-Positive Metastatic Breast Cancer: A Retrospective Analysis","volume":"41","author":"Lv","year":"2018","journal-title":"Oncol. Res. Treat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1200\/JCO.2014.55.5730","article-title":"Trastuzumab plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2\u2013Positive Breast Cancer: Planned Joint Analysis of Overall Survival from NSABP B-31 and NCCTG N9831","volume":"32","author":"Perez","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.25259\/IJPP_390_2021","article-title":"Comparison of Adverse Effects of Trastuzumab with Other Drug Combinations for the Treatment of Breast Cancer: A Review","volume":"66","author":"Kumar","year":"2022","journal-title":"Indian J. Physiol. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.5603\/KP.2016.0156","article-title":"2016 ESC Position Paper on Cancer Treatments and Cardiovascular Toxicity Developed under the Auspices of the ESC Committee for Practice Guidelines","volume":"74","author":"Zamorano","year":"2016","journal-title":"Kardiologia Polska"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","article-title":"2022 ESC Guidelines on Cardio-Oncology Developed in Collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"23","author":"Lyon","year":"2022","journal-title":"Eur. Hear. J. -Cardiovasc. Imaging"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1093\/annonc\/mdv213","article-title":"Six versus 12 Months of Adjuvant Trastuzumab in Combination with Dose-Dense Chemotherapy for Women with HER2-Positive Breast Cancer: A Multicenter Randomized Study by the Hellenic Oncology Research Group (HORG)","volume":"26","author":"Mavroudis","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1016\/S0140-6736(19)30650-6","article-title":"6 versus 12 Months of Adjuvant Trastuzumab for HER2-Positive Early Breast Cancer (PERSEPHONE): 4-Year Disease-Free Survival Results of a Randomised Phase 3 Non-Inferiority Trial","volume":"393","author":"Earl","year":"2019","journal-title":"Lancet"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","article-title":"Early Breast Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up\u2020","volume":"30","author":"Cardoso","year":"2019","journal-title":"Ann. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2562","DOI":"10.1093\/eurheartj\/ehab843","article-title":"A Systematic Review and Meta-Analysis of Beta-Blockers and Renin\u2013Angiotensin System Inhibitors for Preventing Left Ventricular Dysfunction due to Anthracyclines or Trastuzumab in Patients with Breast Cancer","volume":"43","author":"Lewinter","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.amjcard.2019.05.046","article-title":"Meta-Analysis Comparing Usefulness of Beta Blockers to Preserve Left Ventricular Function during Anthracycline Therapy","volume":"124","author":"Shah","year":"2019","journal-title":"Am. J. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.ejca.2013.04.030","article-title":"Role of Cardioprotective Therapy for Prevention of Cardiotoxicity with Chemotherapy: A Systematic Review and Meta-Analysis","volume":"49","author":"Kalam","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_22","first-page":"19","article-title":"The Role of Cardioprotection in Cancer Therapy Cardiotoxicity","volume":"4","author":"Omland","year":"2022","journal-title":"JACC: CardioOncology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/jjco\/hyx068","article-title":"Cardio-Oncology: A Multidisciplinary Approach for Detection, Prevention and Management of Cardiac Dysfunction in Cancer Patients","volume":"47","author":"Tajiri","year":"2017","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e015327","DOI":"10.1161\/JAHA.119.015327","article-title":"The Role of Angiotensin-Converting Enzyme Inhibitors and \u03b2-Blockers in Primary Prevention of Cardiac Dysfunction in Breast Cancer Patients","volume":"9","author":"Brown","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Brown, L.J., Meredith, T., Yu, J., Patel, A., Neal, B., Arnott, C., and Lim, E. (2021). Heart Failure Therapies for the Prevention of HER2-Monoclonal Antibody-Mediated Cardiotoxicity: A Systematic Review and Meta-Analysis of Randomized Trials. Cancers, 13.","DOI":"10.3390\/cancers13215527"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s10552-021-01487-1","article-title":"Statins to Mitigate Cardiotoxicity in Cancer Patients Treated with Anthracyclines And\/or Trastuzumab: A Systematic Review and Meta-Analysis","volume":"32","author":"Obasi","year":"2021","journal-title":"Cancer Causes Control"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"103006","DOI":"10.1016\/j.critrevonc.2020.103006","article-title":"The Role of Cardio-Protective Agents in Cardio-Preservation in Breast Cancer Patients Receiving Anthracyclines \u00b1 Trastuzumab: A Meta-Analysis of Clinical Studies","volume":"153","author":"Elghazawy","year":"2020","journal-title":"Crit. Rev. Oncol. \/Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 Statement: An Updated Guideline for Reporting Systematic Reviews","volume":"372","author":"Page","year":"2021","journal-title":"Br. Med. J."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: A Revised Tool for Assessing Risk of Bias in Randomised Trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Higgins, J., Green, S., and Ben Van Den, A. (2008). Cochrane Handbook for Systematic Reviews of Interventions, Wiley.","DOI":"10.1002\/9780470712184"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1001\/jamaoncol.2021.3395","article-title":"Cardioprotective Strategy for Patients with Nonmetastatic Breast Cancer Who Are Receiving an Anthracycline-Based Chemotherapy: A Randomized Clinical Trial","volume":"7","author":"Livi","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of Cardiac Dysfunction during Adjuvant Breast Cancer Therapy (PRADA): A 2 \u00d7 2 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_34","first-page":"206","article-title":"Evaluation of the Preventive Effects of Carvedilol on Trastuzumab-Induced Cardiotoxicity in Early-Stage and Locally Advanced HER2-Positive Breast Cancer Patients","volume":"15","author":"Esfandbod","year":"2021","journal-title":"Int. J. Hematol. -Oncol. Stem Cell Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","article-title":"Randomized Trial of Lisinopril versus Carvedilol to Prevent Trastuzumab Cardiotoxicity in Patients with Breast Cancer","volume":"73","author":"Guglin","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","article-title":"Multidisciplinary Approach to Novel Therapies in Cardio-Oncology Research (MANTICORE 101\u2013Breast): A Randomized Trial for the Prevention of Trastuzumab-Associated Cardiotoxicity","volume":"35","author":"Pituskin","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","article-title":"Angiotensin II\u2013Receptor Inhibition with Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients with Early Breast Cancer","volume":"2","author":"Boekhout","year":"2016","journal-title":"JAMA Oncol."},{"key":"ref_38","first-page":"20","article-title":"Efficacy of Treatment With Carvedilol in Preventing Early-Stage Left Ventricular Dysfunction in Patients With Breast Cancer Candidated to Receive Trastuzumab Using 2D Speckle-Tracking Echocardiography","volume":"20","author":"Farahani","year":"2019","journal-title":"Iran. Heart J."},{"key":"ref_39","first-page":"173","article-title":"Assessment of Carvedilol Therapy in Prevention of Heart Failure in HER2 Positive Breast Cancer Patients Receiving Trastuzumab","volume":"57","author":"Sherafati","year":"2019","journal-title":"Acta Med. Iran."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","article-title":"Prevention of Cardiac Dysfunction during Adjuvant Breast Cancer Therapy (PRADA): Extended Follow-up of a 2\u00d72 Factorial, Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Candesartan and Metoprolol","volume":"143","author":"Heck","year":"2021","journal-title":"Circulation"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3910","DOI":"10.1200\/JCO.2009.27.3615","article-title":"Trastuzumab-Induced Cardiotoxicity: Clinical and Prognostic Implications of Troponin I Evaluation","volume":"28","author":"Cardinale","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Grela-Wojewoda, A., P\u00fcsk\u00fcll\u00fco\u011flu, M., Sas-Korczy\u0144ska, B., Zeme\u0142ka, T., Pacholczak-Madej, R., Wysocki, W.M., Wojewoda, T., Adamczyk, A., Lompart, J., and Korman, M. (2022). Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2- Positive Breast Cancer Patient Population. Cancers, 14.","DOI":"10.3390\/cancers14143353"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3901","DOI":"10.1200\/JCO.2010.30.6274","article-title":"Troponin I Provides Insight into Cardiotoxicity and the Anthracycline-Trastuzumab Interaction","volume":"28","author":"Ewer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s10549-017-4628-3","article-title":"Cardiac Biomarkers for Early Detection and Prediction of Trastuzumab And\/or Lapatinib-Induced Cardiotoxicity in Patients with HER2-Positive Early-Stage Breast Cancer: A NeoALTTO Sub-Study (BIG 1-06)","volume":"168","author":"Ponde","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1200\/JCO.2015.65.7916","article-title":"Evandro de Azambuja. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients with Early-Stage Human Epidermal Growth Factor Receptor 2\u2013Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy","volume":"35","author":"Zardavas","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Khan, G., Alam, M.F., Alshahrani, S., Almoshari, Y., Jali, A.M., Alqahtani, S., Khalid, M., Nasar, S., and Anwer, T. (2023). Trastuzumab-Mediated Cardiotoxicity and Its Preventive Intervention by Zingerone through Antioxidant and Inflammatory Pathway in Rats. J. Pers. Med., 13.","DOI":"10.3390\/jpm13050750"}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/7\/983\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:09:22Z","timestamp":1760126962000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/7\/983"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,9]]},"references-count":48,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ph16070983"],"URL":"https:\/\/doi.org\/10.3390\/ph16070983","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,9]]}}}